School of Integrated Health Sciences News
With many degree offerings that are accredited by national organizations, the School of Integrated Health Sciences offers dynamic classroom instruction, laboratory/clinical practice, research, and mentoring. Our students develop skills that help them break into health-related fields and further their graduate or professional studies.
Current Integrated Health Sciences News
News highlights starring UNLV students and faculty who made local and national headlines.
Alzheimer’s treatment studies offer hope as UNLV expert predicts new potential drugs, biomarkers will yield critical insight for future development.
Carmen Johnson’s self-determination and empathetic personality has led to an impressive increase in the food pantry's usage.
UNLV Law School has 14 top 100 programs in publication’s 2024 rankings, including No. 2 ranking for legal writing; Physical Therapy cracks top 50.
Professor Chih-Huang "Jeffrey" Yu says the new and unique method can make rehab a more effective experience for patients.
A roundup of the top news stories featuring UNLV students and faculty.
Integrated Health Sciences In The News
People with Down syndrome experience physical difficulties that can make it more challenging to live an active lifestyle. Researchers at the University of Nevada, Las Vegas CArdiovascular Research and Exercise Lab (CARE Lab) are attempting to assess how a lower heart rate, a feature of Down syndrome, can impact people’s ability to move and exercise.
The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a "learning year" for Alzheimer's drug development.
The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a “learning year” for Alzheimer’s drug development.
Considering current developments in Alzheimer’s drugs, a US expert has predicted that the industry should “be prepared for more complex biological therapies that require intravenous infusion and vigilant monitoring for side effects; more like cancer therapies,” according to Dr Jeffrey Cummings, Alzheimer’s clinician-scientist and research professor at the School of Integrated Health Sciences, University of Nevada, Las Vegas.
The world of Alzheimer’s treatments is at an inflection point as more potential drugs make their way out of clinical trials. And on the heels of newly FDA-approved drugs Aduhelm® (aducanumab) in 2021 and Leqembi® (lecanemab) in 2023, a UNLV researcher says that 2024 is a “learning year” for Alzheimer’s drug development.
The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. On the heels of newly FDA-approved drugs Aduhelm (aducanumab) in 2021 and Leqembi (lecanemab) in 2023, a UNLV researcher says that 2024 is a "learning year" for Alzheimer's drug development.
